[HTML][HTML] Molecular pathology of lung cancer: key to personalized medicine
L Cheng, RE Alexander, GT MacLennan… - Modern Pathology, 2012 - Elsevier
The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR)
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …
mutated or EML4–ALK rearrangement-positive tumors are sensitive to tyrosine kinase …
[HTML][HTML] Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non–small-cell lung cancer after acquired resistance to EGFR-TKI
A Hata, N Katakami, H Yoshioka, R Kaji… - Journal of thoracic …, 2015 - Elsevier
Introduction Epidermal growth factor receptor (EGFR) mutation T790M accounts for
approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Because …
approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Because …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
JJ Yang, HJ Chen, HH Yan, XC Zhang, Q Zhou, J Su… - Lung cancer, 2013 - Elsevier
BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
AB Cortot, CE Repellin, T Shimamura, M Capelletti… - Cancer research, 2013 - AACR
The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited
by the development of drug resistance. The most common mechanism of drug resistance is …
by the development of drug resistance. The most common mechanism of drug resistance is …
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Cancer, 2013 - Wiley Online Library
BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer
Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the …
[HTML][HTML] The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies
C Laface, FM Maselli, AN Santoro, ML Iaia, F Ambrogio… - Pharmaceutics, 2023 - mdpi.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J Gao, HR Li, C Jin, JH Jiang, JY Ding - Clinical and Translational …, 2019 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
SHI Ou - Critical reviews in oncology/hematology, 2012 - Elsevier
The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …